Archives

by in
Entry Author Date Location
Orphan Drug From Scioderm Aims to Treat Rare Skin Disease 10/07/14 Raleigh Durham
Editor’s Picks: Xconomy Boston’s Top 20 Stories of Q1 2013 04/01/13 Boston
Third Rock Stocks Up With $516M New Fund, Looks to Start 16 Cos 03/25/13 Boston
Biotech VCs Aren’t Lemmings Anymore. They’re Lone Rangers 03/25/13 National
East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist 03/01/13 Boston
Third Rock’s Bet on Lotus Tissue Repair Generates Big Return 02/27/13 Boston
East Coast Life Sciences Roundup: Bind, Boston Children’s, J&J, More 01/11/13 Boston
Mid-Priced Biotechnology Companies Bloom As M&A Targets in 2013 01/10/13 San Francisco
Shire Pharmaceuticals Acquires Lotus Tissue Repair for Undisclosed Sum 01/09/13 Boston
Shire Buys Third Rock’s Lotus Tissue Repair 01/08/13 Boston
Sabet and Wilson Out at Twitter, Hirshland Out at Polaris, & More VC Comings and Goings 09/22/11 Boston
VC Investments in Boston Companies Soar to 1999 Levels ($1B+); Here Are the Top 10 Deals from the 2nd Quarter 07/21/11 Boston
Zynga Files For IPO, Brightcove Inks Boston Lease, Lotus Adds $26M, & More Boston-Area Deals News 07/06/11 Boston
Acetylon Adds $27M, Third Rock Leads Lotus Round, InfraReDx Gets $24M, & More Boston-Area Life Sciences News 07/01/11 Boston
Lotus Pioneers New Treatment for Rare and Disfiguring Disorder, Raises $26 Million From Third Rock 06/30/11 Boston
Lotus Tissue Repair Lands $26,000,000 Series A Financing Round 06/30/11 Boston
Page 1 of 1